株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

重症急性呼吸器症候群 (SARS) コロナウイルス感染症:パイプライン分析

Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 255961
出版日 ページ情報 英文 52 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.53円で換算しております。
Back to Top
重症急性呼吸器症候群 (SARS) コロナウイルス感染症:パイプライン分析 Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2017
出版日: 2017年08月22日 ページ情報: 英文 52 Pages
概要

重症急性呼吸器症候群 (SARS) は、コロナウイルス科のウイルスによって引き起こされる、重篤で、生命に関わる恐れのあるウイルス感染症です。咳、悪寒や震え、頭痛、筋肉痛、下痢、めまい、悪心や嘔吐などの症状が見られます。危険因子として、免疫系の遺伝子変異、感染者との緊密な接触が挙げられます。

当レポートでは、重症急性呼吸器症候群 (SARS) コロナウイルス感染症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤プロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

重症急性呼吸器症候群 (SARS) コロナウイルス感染症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • CEL-SCI Corporation
  • GeneCure LLC
  • Humabs BioMed SA
  • Inovio Pharmaceuticals, Inc.
  • Nanotherapeutics, Inc.
  • Novavax, Inc.
  • Phelix Therapeutics, LLC
  • Protein Sciences Corporation

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • CEL-1000
  • D-3252
  • 感染症向け Cathepsin L阻害薬
  • FDX-000
  • INO-4500
  • LCA-60
  • 中東呼吸器症候群ワクチン + 重症急性呼吸器症候群ワクチン
  • ML-188
  • SARSウィルス感染症向けモノクローナル抗体
  • RBD-219N1
  • SARS (ウイルス様粒子) ワクチン
  • SARS ワクチン
  • SARSワクチン
  • SARS・エボラウィルス感染症向け Cathepsin L 阻害小分子
  • SSYA-10001
  • thiocarbazate

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9645IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2017, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.

Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Severe Acute Respiratory Syndrome (SARS) - Overview
    • Severe Acute Respiratory Syndrome (SARS) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development
    • 3-V Biosciences Inc
    • Atriva Therapeutics GmbH
    • Autoimmune Technologies LLC
    • CEL-SCI Corp
    • Fab'entech SA
    • GeneCure LLC
    • Gilead Sciences Inc
    • Nanotherapeutics Inc
    • Novavax Inc
    • Oncovir Inc
    • Phelix Therapeutics LLC
    • Protein Sciences Corp
  • Severe Acute Respiratory Syndrome (SARS) - Drug Profiles
    • ATR-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSW-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-3252 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit Cathepsin L for Coronaviridae Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-5734 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ML-188 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for SARS Virus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Poly-ICLC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SARS (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • severe acute respiratory syndrome vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • severe acute respiratory syndrome vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SSYA-10001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TVB-3567 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Severe Acute Respiratory Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Severe Acute Respiratory Syndrome (SARS) - Dormant Projects
  • Severe Acute Respiratory Syndrome (SARS) - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by 3-V Biosciences Inc, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Atriva Therapeutics GmbH, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Autoimmune Technologies LLC, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by CEL-SCI Corp, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Fab'entech SA, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by GeneCure LLC, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Gilead Sciences Inc, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Nanotherapeutics Inc, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Novavax Inc, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Oncovir Inc, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Phelix Therapeutics LLC, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Protein Sciences Corp, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top